State of Wyoming Sells 36,106 Shares of Indivior PLC (NASDAQ:INDV)

State of Wyoming lowered its holdings in Indivior PLC (NASDAQ:INDV - Free Report) by 47.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,738 shares of the company's stock after selling 36,106 shares during the period. State of Wyoming's holdings in Indivior were worth $494,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Stonepine Capital Management LLC increased its stake in shares of Indivior by 13.0% in the fourth quarter. Stonepine Capital Management LLC now owns 305,000 shares of the company's stock valued at $3,791,000 after purchasing an additional 35,000 shares during the period. Man Group plc increased its stake in shares of Indivior by 291.3% in the fourth quarter. Man Group plc now owns 45,365 shares of the company's stock valued at $564,000 after purchasing an additional 33,771 shares during the period. Newtyn Management LLC increased its stake in shares of Indivior by 62.0% in the fourth quarter. Newtyn Management LLC now owns 1,406,531 shares of the company's stock valued at $17,483,000 after purchasing an additional 538,426 shares during the period. Millennium Management LLC increased its stake in shares of Indivior by 36.9% in the fourth quarter. Millennium Management LLC now owns 1,233,006 shares of the company's stock valued at $15,326,000 after purchasing an additional 332,180 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in shares of Indivior in the fourth quarter valued at approximately $57,000. Institutional investors and hedge funds own 60.33% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on INDV. RODMAN&RENSHAW upgraded shares of Indivior to a "strong-buy" rating in a research note on Tuesday, January 28th. Piper Sandler lowered their price objective on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research note on Thursday, March 6th. Finally, Rodman & Renshaw initiated coverage on shares of Indivior in a research note on Tuesday, January 28th. They set a "buy" rating and a $16.00 price objective on the stock.

Indivior Stock Up 0.4%

Indivior stock traded up $0.05 during mid-day trading on Friday, hitting $11.26. The company's stock had a trading volume of 1,303,351 shares, compared to its average volume of 1,022,970. The stock has a market capitalization of $1.55 billion, a P/E ratio of -32.17 and a beta of 0.98. Indivior PLC has a twelve month low of $7.33 and a twelve month high of $18.59. The stock's fifty day moving average price is $10.27 and its two-hundred day moving average price is $10.70.

Indivior (NASDAQ:INDV - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. The company had revenue of $266.00 million during the quarter, compared to analyst estimates of $240.13 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. Equities analysts expect that Indivior PLC will post 1.22 earnings per share for the current year.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.